AAV VARIANTS FOR THE TREATMENT OF DRY AMD

Provided is the intravitreal administration of recombinant adeno-associated virus (rAAV)-based gene therapies for the amelioration of dry-AMD related symptoms, prevention of dry-AMD and treatment of dry-AMD. L'invention concerne l'administration intravitréenne de thérapies géniques à base...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GRISHANIN, Ruslan, DE ALENCASTRO, Gustavo, RILEY, Brigit
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided is the intravitreal administration of recombinant adeno-associated virus (rAAV)-based gene therapies for the amelioration of dry-AMD related symptoms, prevention of dry-AMD and treatment of dry-AMD. L'invention concerne l'administration intravitréenne de thérapies géniques à base de virus adéno-associé recombinant (VAAr) pour l'atténuation de symptômes liés à la DMLA sèche, la prévention de la DMLA sèche et le traitement de la DMLA sèche.